Imexpharm Corp. (IMP) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

INTEREST(Q) At VND 6,177.51 MM has Grown at 180.04%
INTEREST COVERAGE RATIO(Q) Lowest at 2,306.28
DEBT-EQUITY RATIO (HY) Highest at -6.57 %

With ROE of 15.52%, it has a fair valuation with a 3.67 Price to Book Value

Underperformed the market in the last 1 year

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

VND 7,546,439 Million (Small Cap)

P/E

24.00

Industry P/E

Dividend Yield

1.02%

Debt Equity

-0.10

Return on Equity

14.94%

Price to Book

3.43

Revenue and Profits:

Net Sales:

632,696 Million

(Quarterly Results - Jun 2025)

Net Profit:

72,643 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.83%

6 Months

-4.52%

1 Year

-1.82%

2 Years

92.65%

3 Years

-22.24%

4 Years

-36.47%

5 Years

-13.06%

Imexpharm Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.89%

EBIT Growth (5y)

14.65%

EBIT to Interest (avg)

28.50

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

0.94

Tax Ratio

20.94%

Dividend Payout Ratio

25.88%

Pledged Shares

Institutional Holding

ROCE (avg)

20.58%

ROE (avg)

13.53%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.67

EV to EBIT

16.53

EV to EBITDA

13.47

EV to Capital Employed

3.86

EV to Sales

3.16

PEG Ratio

Dividend Yield

0.99%

ROCE (Latest)

23.35%

ROE (Latest)

15.52%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 22.33% vs 17.63% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.20% vs 0.81% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "632,695.80",
          "val2": "517,221.10",
          "chgp": "22.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "142,470.60",
          "val2": "112,222.50",
          "chgp": "26.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6,177.50",
          "val2": "882.90",
          "chgp": "599.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "72,642.90",
          "val2": "65,917.20",
          "chgp": "10.20%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "183.60%",
          "val2": "165.80%",
          "chgp": "1.78%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.59% vs 21.31% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.85% vs 29.44% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,205,119.90",
          "val2": "1,994,036.90",
          "chgp": "10.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "520,794.50",
          "val2": "463,689.20",
          "chgp": "12.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3,590.40",
          "val2": "6,036.20",
          "chgp": "-40.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "297,535.70",
          "val2": "254,622.60",
          "chgp": "16.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "188.30%",
          "val2": "191.10%",
          "chgp": "-0.28%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

632,695.80

517,221.10

22.33%

Operating Profit (PBDIT) excl Other Income

142,470.60

112,222.50

26.95%

Interest

6,177.50

882.90

599.68%

Exceptional Items

0.00

Consolidate Net Profit

72,642.90

65,917.20

10.20%

Operating Profit Margin (Excl OI)

183.60%

165.80%

1.78%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 22.33% vs 17.63% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 10.20% vs 0.81% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,205,119.90

1,994,036.90

10.59%

Operating Profit (PBDIT) excl Other Income

520,794.50

463,689.20

12.32%

Interest

3,590.40

6,036.20

-40.52%

Exceptional Items

0.00

Consolidate Net Profit

297,535.70

254,622.60

16.85%

Operating Profit Margin (Excl OI)

188.30%

191.10%

-0.28%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 10.59% vs 21.31% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.85% vs 29.44% in Dec 2023

All Annual Results

Company CV

About Imexpharm Corp.

Imexpharm Corp.

Pharmaceuticals & Biotechnology

Imexpharm Corporation is a Vietnam-based company engaged in the pharmaceutical industry. The Company manufactures, imports, exports and trades pharmaceutical products, antiseptics, traditional medicine, medical equipment and supplies, cosmetics, supplemental food and drinks. It is also involved in the provision of packaging services and warehousing services for pharmaceutical storage purposes. In addition, the Company is involved in medicinal herb cultivation.

Company Coordinates

Company Details

So 04, Duong 30/04, Phuong 1 , CAO LANH None : None

Tel: 84 27 73851941

http://www.imexpharm.com/

Registrar Details